Breast cancer biomarker measurements and standards

Proteomics - Clinical Applications

Volumn 7, Issue 1-2, 2013, Pages 17-29

  Cole, Kenneth D ^a   He, Hua Jun ^a   Wang, Lili ^a  

^a NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY   (United States)

Author keywords

Breast cancer; Epidermal growth factor receptor; HER2; Reference materials; Standards

Indexed keywords

ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; FORMALDEHYDE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PARAFFIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN C JUN; PROTEIN FOS; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; STEROID RECEPTOR COACTIVATOR 3; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHOSPHORYLATION; BINDING AFFINITY; BREAST CANCER; CANCER CELL CULTURE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CELL ADHESION; CELL DIFFERENTIATION; CELL DIVISION; CELL MIGRATION; CELL TRANSFORMATION; CHOROMOGENIC IN SITU HYBRIDIZATION; COPY NUMBER VARIATION; DIMERIZATION; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DNA MODIFICATION; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOME ANALYSIS; HER2 GENE; HORMONE BINDING; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; ISOTOPE LABELING; LIGAND BINDING; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NATIONAL HEALTH ORGANIZATION; NONHUMAN; NUCLEIC ACID PROBE; NUCLEOTIDE SEQUENCE; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DATABASE; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SUBUNIT; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RNA TRANSCRIPTION; SIGNAL TRANSDUCTION; STANDARDIZATION; TISSUE MICROARRAY; TISSUE PREPARATION; TREATMENT RESPONSE; VALIDATION PROCESS;

BREAST NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84872723383     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201200075     Document Type: Review

References (100)

1. Ross, J. S., Symmans, W. F., Pusztai, L., Hortobagyi, G. N., Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes. Clin. Cancer Res. 2007, 13, 2831-2835.
2. Gown, A. M., Current issues in ER and HER2 testing by IHC in breast cancer. Modern Pathol. 2008, 21, S8-S15.
3. Shah, S., Chen, B. Testing for HER2 in Breast Cancer: A Continuing Evolution. Path. Res. Int. 2011, Art. Num. 903202, 1-16.
4. Bertos, N. r., Park, M., Breast cancer-one term, many entities? J. Clin. Invest. 2011, 121, 3789-3796.
5. Akiyama, T., Sudo, C., Ogawara, H., Toyoshima, K., Yamamoto, T., The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986, 232, 1644-1646.
6. Burgess, A. W., Cho, H. S., Eigenbrot, C., Ferguson, K. M. et al., An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell 2003, 12, 541-552.
7. Carpenter, G., Receptors for epidermal growth-factor and other polypeptide mitogens. Annu. Rev. Biochem. 1987, 56, 881-914.
8. Salomon, D. S., Brandt, R., Ciardiello, F., Normanno, N., Epidermal growth factor-related peptides and their receptors in human malignancies. Critic. Rev. Oncol./Hematol. 1995, 19, 183-232.
9. Yarden, Y., Sliwkowski, M. X., Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2, 127-137.
10. Olayioye, M. A., Graus-Porta, D., Beerli, R. R., Rohrer, J. et al., ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol. Cell. Biol. 1998, 18, 5042-5051.
11. Herbst, R. S., Review of epidermal growth factor receptor biology. Int. J. Rad. Oncol. Biol. Phys. 2004, 59, 21-26.
12. Giehl, K., Skripczynski, B., Mansard, A., Menke, A. et al., Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration. Oncogene 2000, 19, 2930-2942.
13. Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A. et al., Insect cell-expressed P180(ErbB3) possesses an impaired tyrosine kinase-activity. PNAS (USA) 1994, 91, 8132-8136.
14. Klapper, L. N., Glathe, S., Vaisman, N., Hynes, N. E. et al., The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. PNAS (USA) 1999, 96, 4995-5000.
15. Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O. et al., ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987, 237, 178-182.
16. Hudziak, R. M., Schkessinger, J., Ullrich, A., Increased expression of the putative growth-factor receptor P185HER2 causes transfornation and tumorigenesis of NIH 3T3 cells. PNAS (USA) 1987, 84, 7159-7163.
17. Li, J. J., Chen, F., Cona, M. M., Feng, Y. B. et al., A review on various targeted anticancer therapies. Targ. Oncol. 2012, 7, 69-85.
18. Saal, L. H., Holm, K., Maurer, M., Memeo, L. et al., PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005, 65, 2554-2559.
19. Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M. et al., An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008, 68, 6084-6091.
20. Valabrega, G., Montemurro, F., Aglietta, M., Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann. Oncol. 2007, 18, 977-984.
21. Cho, H. S., Mason, K., Ramyar, K. X., Stanley, A. M. et al., Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421, 756-760.
22. Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C. et al., American society of clinical oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 2010, 16, 2784-2795.
23. Criscitiello, C., Fumagalli, D., Saini, K. S., Loi, S., Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection. OncoTargets Ther. 2011, 4, 1-11.
24. Bardou, V. J., Arpino, G., Elledge, R. M., Osborne, C. K. et al., Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol. 2003, 21, 1973-1979.
25. Nicholson, R. I., McCelland, R. A., Robertson, J. F. R., Gee, J. M. W., Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr. Relat Cancer 1999, 6, 373-387.
26. Hammes, S. R., Levin, E. R., Extranuclear steroid receptors: nature and actions. Endocr. Rev. 2007, 28, 726-741.
27. Roy, S. S., Vadkamudi, R. K., Role of estrogen receptor signaling in breast cancer metastasis. Int. J. Breast Cancer 2012, 2012 Article Article ID 654698, 1-8.
28. Pedram, A., Razandi, M., Levin, E. R., Nature of functional estrogen receptors at the plasma membrane. Mol. Endocrinol. 2006, 16, 938-946.
29. Anzick, S. L., Kononen, J., Walker, R. L., Azorsa, D. O. et al., AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997, 277, 965-968.
30. Osborne, C. K., Bardou, V., Hopp, T. A., Chamness, G. C. et al., Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl. Cancer Inst. 2003, 95, 353-361.
31. Loi, S., Haibe-Kains, B., Desmedt, C., Wirapati, P. et al., Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008, 9, 239.
32. Carlson, R. W., Moench, S. J., Hammond, W. W., Perez, E. A. et al., HER2 testing in breast cancer: NCCN task force report and recommendations. J. Nat. Compr. Cancer Netw. 2006, 4, S1-S23.
33. Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L. et al., American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med. 2007, 131, 18-43.
34. Khoury, T., Sait, S., Hwang, H., Chandrasekhar, R. et al., Delay to formalin fixation effect on breast biomarkers. Mod. Pathol. 2009, 22, 1457-1467.
35. Rhodes, A., Jasani, B., Anderson, E., Dodson, A. et al., Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors-a comparative study involving results from laboratories in 21 countries. Am. J. Clin. Pathol. 2002, 118, 408-417.
36. Xiao, Y., Gao, X., Maragh, S., Telford, W. et al., Cell lines as candidate reference materials for quality control of ERBB2 amplification and expression assays in breast cancer. Clin. Chem. 2009, 55, 1307-1315.
37. Wilson, K. S., Roberts, H., Leek, R., Harris, A. L. et al., Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. Am. J. Clin. Pathol. 2002, 161, 1171-1185.
38. Sorlie, T., Tibshirani, R., Parker, J., Hastie, T. et al., Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS (USA) 2003, 100, 8418-8423.
39. Bergamaschi, A., Kim, Y. H., Wang, P., Sorlie, T. et al., Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 2006, 45, 1033-1040.
40. Shadeo, A., Lam, W., Comprehensive copy number profiles of breast cancer cell model genomes. Breast Cancer Res. 2006, 8, R9.
41. Neve, R., Chin, K., Fridlyand, J., Yeh, J. et al., A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10, 515-527.
42. Kao, J., Salari, K., Bocanegra, M., Choi, Y. L. et al., Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS ONE 2009, 4, e6146, 1-16.
43. The Cancer Genome Atlas Network, comprehensive molecular portraits of human breast cancer. Nature 2012, 490, 61-70.
44. Paik, S., Shak, S., Tang, G., Kim, C. et al., A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 2004, 351, 2817-2826.
45. van't Veer, L. J., Dai, H. Y., van de Vijver, M. J., He, Y. D. D. et al., Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415, 530-536.
46. Knauer, M., Mook, S., Rutgers, E. J. T., Bender, R. A. et al., The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res. Treat. 2010, 120, 655-661.
47. Guedj, M., Marisa, L., de Reynies, A., Orsetti, B. et al., A refined molecular taxonomy of breast cancer. Oncogene 2012, 31, 1196-1206.
48. Lehmann, U., Glockner, S., Kleeberger, W., Feist, H. et al., Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. Am. J. Pathol. 2000, 156, 1855-1864.
49. Bustin, S. A., Benes, V., Garson, J. A., Hellemans, J. et al., The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 2009, 55, 611-622.
50. Beisvag, V., Kauffmann, A., Malone, J., Foy, C. et al., Contributions of the EMERALD project to assessing and improving microarray data quality. Biotechniques 2011, 50, 27-31.
51. Jiang, L. C., Schlesinger, F., Davis, C. A., Zhang, Y. et al., Synthetic spike-in standards for RNA-seq experiments. Genome Res. 2011, 21, 1543-1551.
52. Boshetti, E., Chung, M. C. M., Righetti, P. G., "The quest for biomarkers": are we on the right technical track? Proteomics Clin. Appl. 2012, 6, 22-41.
53. He, H. J., Zong, Y., Kole, S., Bernier, M. et al., Sensing the insulin signaling pathway with an antibody array. Proteomics Clin. Appl. 2009, 3, 1441-1450.
54. Brennan, D. J., O'Connor, D. P., Rexhepaj, E., Ponten, F. et al., Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat. Rev. Cancer 2010, 10, 605-617.
55. Tibes, R., Qiu, Y., Lu, Y., Hennessy, B. et al., Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol. Cancer Ther. 2012, 5, 2512-2521.
56. Wolf-Yadlin, A., Hautaniemi, S., Lauffenburger, D. A., White, F. M., Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks. PNAS (USA) 2007, 104, 5860-5865.
57. Myers, M. V., Manning, H. C., Coffey, R. J., Liebler, D. C., Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling. Mol. Cell. Proteomics 2012, 11, 1-15.
58. Schoenherr, R. M., Whiteaker, J. R., Zhao, L., R.G ., I. et al., Multiplexed quantitation of estrogen receptor and HER2/Neu in tissue and cell lysates by peptide immunoassay enrichment mass spectrometry. Proteomics 2012, 1253-1260.
59. Sprung, R. W., Martinez, M. A., Carpenter, K. L., Ham, A. J. L. et al., Precision of multiple reaction monitoring mass spectrometry analysis of formalin-fixed, paraffin-embedded tissue. J. Proteome Res. 2012, 11, 3498-3505.
60. Hembrough, T., Thyparambil, S., Liao, W. L., Darfler, M. M. et al., Selected reaction monitoring (SRM) analysis of epidermal growth factor receptor (EGFR) in formalin fixed tumor tissue. Clin. Proteomics 2012, 9, 1-10.
61. Harsha, H. C., Molina, H., Pandey, A., Quantitative proteomics using stable isotope labeling with amino acids in culture. Nat. Prot. 2008, 3, 505-516.
62. Andersen, J. N., Sathyanarayanan, S., Di Bacco, A., Chi, A. et al., Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci. Trans. Med. 2010, 4, Article Number 43ra55, 1-14.
63. Chen, H., Pimienta, G., Gu, Y., Sun, X. et al., Proteomic characterization of Her2/neu-overexpressing breast cancer cells. Proteomics 2010, 10, 3800-3810.
64. Tabb, D. L., Vega-Montoto, L., Rudnick, P. A., Variyath, A. M. et al., Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry. J. Proteome Res. 2010, 9, 761-776.
65. Rudnick, P. A., Clauser, K. R., Kilpatrick, L. E., Tchekhovskoi, D. V. et al., Performance metrics for liquid chromatography-tandem mass spectrometry systems in proteomics analyses. Mol. Cell. Proteomics 2010, 9, 225-241.
66. Paulovich, A. G., Billheimer, D., Ham, A. J., Vega-Montoto, L. et al., Interlaboratory study characterizing a yeast performance standard for benchmarking LC-MS platform performance. Mol. Cell. Proteomics 2009, 9, 242-254.
67. Addona, T. A., Abbatiello, S. E., Schilling, B., Skates, S. J. et al., Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat. Biotech. 2009, 27, 633-641.
68. Engel, K. B., Moore, H. M., Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. Arch. Pathol. Lab. Med. 2011, 135, 537-543.
69. Xie, R., Chung, J. Y., Ylaya, K., Williams, R. L. et al., Factors influencing the degradation of archival formalin-fixed paraffin-embedded tissue sections. J. Histochem. Cytochem. 2011, 59, 356-365.
70. Shi, S. R., Key, M. E., Kalra, K. L., Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J. Histochem. Cytochem. 1991, 39, 741-748.
71. Tanca, A., Pagnozzi, D., Addis, M. F., Setting proteins free: progresses and achievements in proteomics of formalin-fixed, paraffin-embedded tissues. Proteomic Clin. Appl. 2012, 6, 7-21.
72. Gilbert, M. T. P., Haselkorn, T., Bunce, M., Sanchez, J. J. et al., The isolation of nucleic acids from fixed, paraffin-embedded tissues-which methods are useful when? PLOS One 2007, 2, e537.
73. Espina, V., Edmiston, K. H., Heiby, M., Pierobon, M. et al., A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol. Cell. Proteomics 2008, 7, 1998-2018.
74. Svensson, M., Boren, M., Skold, K., Falth, M. et al., Heat stabilization of the tissue proteome: a new technology for improved proteomics. J. Proteome Res. 2009, 8, 974-981.
75. Lundby, A., Secher, A., Lage, K., Nordsborg, N. B. et al., Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat. Comm. 2012, 3, 876.
76. Ma, Y., Dai, H. L., Kong, X. M., Impact of warm ischemia on gene expression analysis in surgically removed biosamples. Anal. Biochem. 2012, 423, 229-235.
77. Hayashi, N., Nakamura, S., Tokuda, Y., Shimoda, Y. et al., Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int. J. Clin. Oncol. 2012, 17, 96-104.
78. Meng, S. D., Tripathy, D., Shete, S., Ashfaq, R. et al., HER-2 gene amplification can be acquired as breast cancer progresses. PNAS (USA) 2004, 101, 9393-9398.
79. Gartler, S., Apparent HeLa cell line contamination of human heteroploid cell lines. Nature 1968, 217, 750-751.
80. Nelson-Rees, W. A., Daniels, D. W., Flandermeyer, R. R., Cross-contamination of cells in culture. Science 1981, 212, 446-452.
81. MacLeod, R. A. F., Dirks, W. G., Matsuo, Y., Kaufmann, M. et al., Widespread intraspecies cross-contamination of human tumor cell lines arising at source. Intern. J. Cancer 1999, 83, 555-563.
82. Liscovitch, M., Ravid, D., A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. Cancer Lett. 2007, 245, 350-352.
83. Rae, J. M., Creighton, C. J., Meck, J. M., Haddad, B. R. et al., MDA-MB-435 cells are derived from M14 melanoma cells-a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res. Treat. 2007, 104, 13-19.
84. Hughes, P., Marshall, D., Reid, Y., Parkes, H. et al., The costs of using unauthenticated, over-passaged cell lines: how much more data do we need? Biotechniques 2007, 43, 575-582.
85. Butler, J. M., Fundamentals of Forensic DNA Typing, Academic Press, New York 2010.
86. Masters, J. R., Thomson, J. A., Daly-Burns, B., Reid, Y. A. et al., Short tandem repeat profiling provides an international reference standard for human cell lines. PNAS (USA) 2001, 98, 8012-8017.
87. Barallon, R., Bauer, S. R., Butler, J., Capes-Davis, A. et al., Recommendation of short tandem repeat profiling for authenticating human cell lines, stem cells, and tissues. In Vitro Cell Dev. Biol. Anim. 2010, 46, 727-732.
88. Almeida, J. L., Hill, C. R., Cole, K. D., Authentication of African green monkey cell lines using human short tandem repeat markers. BMC Biotech. 2011, 11, 102-111.
89. Draper, J. S., Smith, K., Gokhale, P., Moore, H. D. et al., Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. Nat. Biotech. 2003, 22, 53-54.
90. Maitra, A., Arking, D. E., Shivapurkar, N., Ikeda, M. et al., Genomic alterations in cultured human embryonic stem cells. Nat. Genet. 2005, 37, 1099-1103.
91. Osborne, C. K., Hobbs, K., Trent, J. M., Biological differences among MCF-7 breast cancer cell-lines from different laboratories. Breast Cancer Res. Treat. 1987, 9, 111-121.
92. Bahia, H., Ashman, J. N. E., Cawkwell, L., Lind, M. et al., Karyotypic variation between independently cultured strains of the cell line MCF-7 identified by multicolour fluorescence in situ hybridization. Int. J. Oncol. 2002, 20, 489-494.
93. Tlsty, T. D., Coussens, L. M., Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. Mech. Dis. 2006, 1, 119-150.
94. Król, M., Pawlowski, K. M., Majchrzak, K., Gajewska, M. et al., Global gene expression profiles of canine macrophages and canine mammary cancer cells grown as a co-culture in vitro. BMC Vet. Res. 2012, 8, Article Number 16, 1-20.
95. Krol, M., Pawlowski, K. M., Szyszko, K., Maciejewski, H. et al., The gene expression profiles of canine mammary cancer cells grown with carcinoma-associated fibroblasts (CAFs) as a co-culture in vitro. BMC Vet. Res. 2012, 8, Article Number 35, 1-22.
96. Burdall, S., Hanby, A., Lansdown, M., Speirs, V., Breast cancer cell lines: friend or foe? Breast Cancer Res. 2003, 5, 89-95.
97. Gazdar, A. F., Kurvari, V., Virmani, A., Gollahon, L. et al., Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Intern. J. Cancer 1998, 78, 766-774.
98. Wang, L., Cole, K. D., Peterson, A., Gaigalas, A. K. et al., Monoclonal antibody selection for interleukin-4 quantification using suspension arrays and forward-phase protein microarrays. J. Proteome Res. 2007, 6, 4720-4727.
99. Bordeaux, J., Welsh, A. W., Agarwal, S., Killiam, E. et al., Antibody validation. Biotechniques 2010, 48, 197-209.
100. Ponten, F., Schwenk, J. M., Asplund, A., Edqvist, P. H. D., The Human Protein Atlas as a proteomic resource for biomarker discovery. J. Intern. Med. 2011, 270, 428-446.